Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.42 - $0.68 $51,408 - $83,232
122,400 Added 133.19%
214,300 $92,000
Q1 2023

May 12, 2023

SELL
$0.56 - $1.07 $2,520 - $4,815
-4,500 Reduced 4.67%
91,900 $58,000
Q4 2022

Feb 13, 2023

SELL
$0.58 - $17.99 $11,136 - $345,407
-19,200 Reduced 16.61%
96,400 $73,000
Q3 2022

Nov 14, 2022

BUY
$0.91 - $14.63 $55,146 - $886,578
60,600 Added 110.18%
115,600 $110,000
Q2 2022

Aug 12, 2022

BUY
$0.89 - $2.47 $3,293 - $9,139
3,700 Added 7.21%
55,000 $63,000
Q1 2022

May 13, 2022

SELL
$1.63 - $2.55 $5,542 - $8,670
-3,400 Reduced 6.22%
51,300 $123,000
Q4 2021

Feb 11, 2022

SELL
$2.27 - $3.0 $304,116 - $401,916
-133,972 Reduced 71.01%
54,700 $132,000
Q3 2021

Nov 12, 2021

SELL
$2.45 - $4.1 $184,776 - $309,217
-75,419 Reduced 28.56%
188,672 $575,000
Q2 2021

Aug 13, 2021

SELL
$3.0 - $4.39 $148,623 - $217,484
-49,541 Reduced 15.8%
264,091 $1.03 Million
Q1 2021

May 13, 2021

SELL
$2.2 - $5.05 $78,474 - $180,133
-35,670 Reduced 10.21%
313,632 $1.12 Million
Q4 2020

Feb 10, 2021

BUY
$1.85 - $2.54 $137,961 - $189,417
74,574 Added 27.14%
349,302 $754,000
Q3 2020

Nov 13, 2020

SELL
$1.85 - $2.57 $269,580 - $374,497
-145,719 Reduced 34.66%
274,728 $555,000
Q2 2020

Aug 13, 2020

BUY
$1.59 - $2.51 $613,700 - $968,797
385,975 Added 1119.68%
420,447 $854,000
Q1 2020

May 14, 2020

SELL
$1.39 - $3.19 $370,852 - $851,092
-266,800 Reduced 88.56%
34,472 $59,000
Q4 2019

Feb 13, 2020

BUY
$1.96 - $2.81 $289,296 - $414,756
147,600 Added 96.05%
301,272 $777,000
Q3 2019

Nov 13, 2019

BUY
$2.12 - $9.37 $259,640 - $1.15 Million
122,472 Added 392.54%
153,672 $352,000
Q2 2019

Aug 12, 2019

BUY
$6.27 - $9.48 $101,574 - $153,576
16,200 Added 108.0%
31,200 $284,000
Q1 2019

May 14, 2019

BUY
$7.01 - $10.24 $105,150 - $153,600
15,000 New
15,000 $114,000

Others Institutions Holding SYBX

About SYNLOGIC, INC.


  • Ticker SYBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,229,600
  • Market Cap $105M
  • Description
  • Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...
More about SYBX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.